Switch theme
Sign up to access all valuation multiples
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
2016
n/a
Last FY Revenue $11.4M
Last FY EBITDA -$6.6M
$47.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Applied BioCode achieved revenue of $11.4M and an EBITDA of -$6.6M.
Applied BioCode expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Applied BioCode valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $11.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $6.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 59% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -58% | XXX | XXX | XXX |
| EBIT | XXX | -$9.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -81% | XXX | XXX | XXX |
| Net Profit | XXX | -$8.7M | XXX | XXX | XXX |
| Net Margin | XXX | -76% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Applied BioCode's stock price is TWD 21 (or $1).
Applied BioCode has current market cap of TWD 2.2B (or $73.0M), and EV of TWD 1.4B (or $47.3M).
See Applied BioCode trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47.3M | $73.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Applied BioCode has market cap of $73.0M and EV of $47.3M.
Applied BioCode's trades at 4.1x EV/Revenue multiple, and -7.2x EV/EBITDA.
Equity research analysts estimate Applied BioCode's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Applied BioCode's P/E ratio is not available.
See valuation multiples for Applied BioCode and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73.0M | XXX | $73.0M | XXX | XXX | XXX |
| EV (current) | $47.3M | XXX | $47.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -5.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -8.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApplied BioCode's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Applied BioCode's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Applied BioCode's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Applied BioCode and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -58% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 79% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 140% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Applied BioCode acquired XXX companies to date.
Last acquisition by Applied BioCode was XXXXXXXX, XXXXX XXXXX XXXXXX . Applied BioCode acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Applied BioCode founded? | Applied BioCode was founded in 2016. |
| Where is Applied BioCode headquartered? | Applied BioCode is headquartered in Taiwan. |
| Is Applied BioCode publicy listed? | Yes, Applied BioCode is a public company listed on TAI. |
| What is the stock symbol of Applied BioCode? | Applied BioCode trades under 6598 ticker. |
| When did Applied BioCode go public? | Applied BioCode went public in 2017. |
| Who are competitors of Applied BioCode? | Similar companies to Applied BioCode include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Applied BioCode? | Applied BioCode's current market cap is $73.0M |
| Is Applied BioCode profitable? | Yes, Applied BioCode is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
